| 영문 | antiglobulin antibody | 한글 | 항글로불린항체 |
|---|---|---|---|
| 설명 | 항체에 대한 항체, 즉 특정 항체와 결합할 수 있는 항체. 대개 인간의 항체를 쥐에 주사하여 쥐로 하여금 인간 항체에 대한 항체를 만들게 한다(쥐에 있어서는 인간의 항체도 외부에서 들어온 물질이므로). 이것은 여러 가지 실험에서 인간의 특정항체를 검출하는데 이용한다. |
||
| 영문 | antibody | 한글 | 항체 |
|---|---|---|---|
| 설명 | 사람의 몸에서 면역에 관계하는 물질. 외부에서 들어온 물질과 꼭 맞게 결합을 하여서 그 물질의 생물학적 활동을 억제하거나 파괴하거나 사람의 다른 면역세포로 하여금 공격하기 용이하게 해주는 기능을 가지고 있다. 항체는 면역글로부린이라는 것으로 이루어져 있고 그 형태에 따라 IgA, IgE, IgG, IgD등으로 나눈다. |
||
| 영문 | serum enzyme | 한글 | 혈청효소 |
|---|---|---|---|
| 설명 | 혈청 내에 포함되어 있는 여러 가지 효소를 일컫는 말이다. |
||
| 영문 | enzyme | 한글 | 효소 |
|---|---|---|---|
| 설명 | 생물체 세포속에서 합성되고, 주로 세포내에서 진행되는 화학반응을 촉매하는 단백질로 시험관내에서도 같은 촉매작용을 한다. 이 효소는 인공적으로 만든 어떤 촉매제보다 그 특이성과 촉매작용이 탁월한 특별한 생체분자이다. 신진대사, 즉 세포내에서 일어나는 물질의 화학적 변환은 효소의 작용에 의해 매우 빠르고 원할하게 이루어진다. 이것은 효소의 촉매 효율이 높은 점과 효소의 기질 특이성 때문이다. 효소반응은 상온, 상압, 최적 pH 등 적절한 조건 아래에서 진행된다. 또 효소의 주체가 단백질이기 때문에 단백질을 변성시키는 열, 강산, 강알칼리, 유기용매 등에 의해 그 작용을 잃는다. 효소는 생체에 널리 분포하며, 복잡하고 다양한 대사반응을 촉매하기 때문에 종류도 많다. 앞서 말한 바와 같이 대부분의 효소는 세포내에 존재하지만, 혈액과 그외의 간질액에 들어 있기도 하고 소화효소류처럼 체외로 분비되는 것도 있다. |
||
| 영문 | enzyme-linked immunoabsorbent assay | 한글 | 효소면역측정법 |
|---|---|---|---|
| 설명 | 효소결합면역흡착제 검정법으로 번역되고 있다. 이 법은 항원(또는 항체)에 알칼리 포스파타아제 또는 페르옥시디아제 등의 산소를 결합시켜 두고 그 산소활성을 지표로 삼아 항원항체반응의 정도를 안 다음 여기에서 항원(또는 항체)의 양을 구하는 것이다. 이 법의 이점으로서 고감도, 조작의 간단함 및 방사선면역측정법처럼 방사성물질을 사용하지 않아도 된다는 점을 들 수 있다. 호르몬이나 면역글로불린의 정량법으로서 응용 되고 있으며 측정용 키트도 시판되고 이있다. |
||
| CT | calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ... |
|---|---|
| IT | immunological test; immunotherapy; implantation test; individual therapy; information technology; in... |
| MT | magnetization transfer; malaria therapy; malignant teratoma; mammary tumor; mammilothalamic tract; m... |
| ACA | abnormal coronary artery; acrodermatitis chronica atrophicans; acute cerebellar ataxia; adenocarcino... |
| GT | gait training; galactosyl transferase; gastrostomy; generation time; genetic therapy; gingiva treatm... |
| ADEPT | Antibody Directed Enzyme Prodrug Therapy |
|---|---|
| GDEPT | Gene directed enzyme prodrug therapy |
| PDPK | Proline-directed protein kinase |
| SDM | Site-directed mutagenesis |
| ERT | Enzyme replacement therapy |
| Antibody Directed Enzyme Prodrug Therapy | <pharmacology> A method for targeting a drug to a specific tissue, in which the targeting agent and the drug are administered separately. The drug is designed to be inactive (a prodrug) until it is converted by an enzyme, which is the targeting agent. The enzyme is coupled to an antibody that directs it to the tissue of interest. When the enzyme arrives at the tissue, the prodrug is activated only at that site, sparing other tissues from potentially toxic side effects. Acronym: ADEPT (14 Nov 1997) |
|---|
| prodrug | A compound that is converted within the body into its active form that has medical effects. Prodrugs useful when the active drug may be too toxic to administer ter systemically, the active drug is absorbed poorly by the digestive tract, or the body breaks down the active drug before it reaches its target. (09 Oct 1997) |
|---|---|
| enzyme replacement therapy | A type of medical treatment for patients who lack an important enzyme, the missing enzyme is injected into the patient. (09 Oct 1997) |
| RNA-directed DNA polymerase | <enzyme> An enzyme that synthesises DNA on an RNA template. It is encoded by the pol gene of retroviruses and by certain retrovirus-like elements. Chemical name: Deoxynucleotide-triphosphate:DNA deoxynucleotidyltransferase (RNA-directed) Registry number: EC 2.7.7.49 (12 Dec 1998) |
| mutagenesis, site-directed | Mutagenesis where the mutation is caused by in vitro induction directed at a specific site in a DNA molecule. The most common method involves use of a chemically synthesised oligonucleotide mutant which can hybridise with the DNA target molecule. The resulting mismatch-carrying DNA duplex may then be transfected into a bacterial cell line and the mutant strands recovered. (12 Dec 1998) |
| site-directed mutagenesis | <molecular biology> Any of several methods used to create specific alterations in a gene. (09 Oct 1997) |
| directed molecular evolution | Techniques used to produce molecules exhibiting properties that conform to the demands of the experimenter. (12 Dec 1998) |
| DNA-directed DNA polymerase | <enzyme> DNA-dependent DNA polymerases found in bacteria, animal and plant cells. During the replication process, these enzymes catalyze the addition of deoxyribonucleotide residues to the end of a DNA strand in the presence of DNA as template-primer. They also possess exonuclease activity and therefore function in DNA repair. Chemical name: Deoxynucleoside-triphosphate:DNA deoxynucleotidyltransferase (DNA-directed) Registry number: EC 2.7.7.7 (12 Dec 1998) |
| DNA-directed RNA polymerase | <enzyme> A group of enzymes that catalyses DNA template-directed extension of the 3'-end of an RNA strand one nucleotide at a time. They can initiate a chain de novo. In eukaryotes, three forms of the enzyme have been distinguished on the basis of sensitivity to alpha-amanitin, and the type of RNA synthesised. Chemical name: Nucleoside-triphosphate:RNA nucleotidyltransferase (DNA-directed) Registry number: EC 2.7.7.6 (12 Dec 1998) |
| other-directed | Pertaining to a person readily influenced by the attitudes of others. (05 Mar 2000) |
| acetyl-activating enzyme | A ligase that catalyses the reaction of acetate and CoA and ATP to form AMP, pyrophosphate, and acetyl-CoA. A key step in the activation of acetate. Synonym: acetate thiokinase, acetate-CoA ligase, acetyl-activating enzyme, acetyl-CoA synthetase. (05 Mar 2000) |
| acyl-activating enzyme | <enzyme> Fatty acid thiokinase (long-chain), a ligase forming acyl-CoA, AMP, and pyrophosphate from long-chain fatty acids, ATP, and coenzyme A. Activity is independent of phosphatidylcholine Registry number: EC 6.2.1.3 Synonym: acyl-activating enzyme, dodecanoyl-CoA synthetase, fatty acid thiokinase (long chain), acid-coenzyme a ligase, fatty acid-CoA ligase, acyl-CoA synthetase, acyl-CoA ligase, coash ligase, ciprofibroyl-CoA synthetase, pristanoyl-CoA synthetase, palmityl CoA synthetase, palmitoyl CoA synthetase, palmitoyl CoA ligase, fatty acyl-CoA synthetase, very long chain fatty acid acyl-CoA synthetase, vlcfa acyl-CoA synthetase, nafenopin-CoA ligase, palmitoyl-CoA synthase, faa2 gene product, faa2p protein, vlacs enzyme (26 Jun 1999) |
| adaptive enzyme | Inducible enzyme, an enzyme that can be detected in a growing culture of a microorganism, after the addition of a particular substance (inducer) to the culture medium, but was not detectable prior to the addition and can act on the inducer. A prototype is the beta-galactosidase of Escherichia coli, synthesised upon the addition of various galactosides, whether or not these are good substrates. Compare: constitutive enzyme. Synonym: adaptive enzyme. (05 Mar 2000) |
| allosteric enzyme | <biochemistry, chemistry> A regulatory enzyme whose activity is modified by the noncovalent binding of a particular metabolite at a site (the allosteric site) other than the active site. (09 Oct 1997) |
| amino acid activating enzyme | <enzyme> Enzymes catalyzing the formation of a specific aminoacyl-tRNA from an amino acid and adenosine 5'-triphosphate with the concomitant formation of adenosine 5'-monophosphate and pyrophosphate. Synonym: amino acid activating enzyme, aminoacyl-tRNA ligases. (05 Mar 2000) |
| angiotensin-converting enzyme | <enzyme> This hydrolase enzyme cleaves the decapeptide angiotensin I (biologically inactive) to form active angiotensin II by angiotensin-converting enzyme which removes a dipeptide (histidylleucine) from angiotensin I. Angiotensin II causes contraction of vascular smooth muscle and thus raises blood pressure and stimulates aldosterone release from the adrenal glands. Angiotensin is finally broken down by angiotensinases. Elevations in angiotensin converting enzyme are seen sarcoidosis, histoplasmosis, alcoholic cirrhosis, asbestosis, berylliosis, diabetes, Hodgkin's disease, hyperthyroidism, amyloidosis, primary biliary cirrhosis, idiopathic pulmonary fibrosis, pulmonary embolism, scleroderma, silicosis, tuberculosis, Gaucher's disease and leprosy. The normal values are 18 to 67 U/ml over 20 years of age (people under 20 have higher levels). Drugs that inhibit ACE are used to treat hypertension and congestive heart failure. See: angiotensin-converting enzyme inhibitor Acronym: ACE (12 Aug 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|